1-6 of 6
Mark DeWitte, VMD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML)

B. Douglas Smith, MD, Andrew W. Roberts, MBBS, PhD, Gail J. Roboz, MD, Mark DeWitte, VMD, Anna Ferguson, BSN, RN, Linda Garrett, RN, Tania Curcio, Kaysey F. Orlowski, Sue Dasen, MS, Debra M. Bensen-Kennedy, MD, Roland B. Walter, MD PhD MS
Journal: Blood
Blood (2015) 126 (23): 3819.
https://doi.org/10.1182/blood.V126.23.3819.3819
Published: 2015
Journal Articles

First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse

B. Douglas Smith, MD, Gail J. Roboz, MD, Roland B. Walter, MD PhD, Jessica K. Altman, MD, Anna Ferguson, BSN, RN, Tania J. Curcio, R.N, Kaysey F. Orlowski, Linda Garrett, RN, Samantha J Busfield, PhD, Megan Barnden, PhD, Brad Sedgmen, PhD, Souravi Ghosh, PhD, Sarah Hosback, PhD, Roslyn Davis, MSc, Allison Dyson, BSc, Sue Dasen, MS, Mark DeWitte, VMD, Debra M. Bensen-Kennedy, MD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2014) 124 (21): 120.
https://doi.org/10.1182/blood.V124.21.120.120
Published: 2014
Journal Articles

Pharmacodynamic Activity and Preclinical Safety of CSL362, a Novel Humanised, Affinity Matured Monoclonal Antibody Against Human Interleukin 3 Receptor

Eva Herzog, Samantha Busfield, PhD, Mark Biondo, PhD, Gino Vairo, Mark DeWitte, VMD, Ingo Pragst, Gerhard Dickneite, Prof. PhD, Andrew Nash, PhD, Sabine Zollner
Journal: Blood
Blood (2012) 120 (21): 1524.
https://doi.org/10.1182/blood.V120.21.1524.1524
Published: 2012
Journal Articles

CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells

Samantha J. Busfield, PhD, Mark Biondo, PhD, Mae Wong, PhD, Hayley S. Ramshaw, PhD, Erwin M Lee, PhD, Kirstee Martin, PhD, Souravi Ghosh, PhD, Hal Braley, Vesna Tomasetig, Con Panousis, PhD, Gino Vairo, PhD, Andrew W. Roberts, MBBS, PhD, Simon Z. He, MBBS, Naomi Sprigg, Daniel Thomas, MBBS, PhD, Mark DeWitte, VMD, Richard B. Lock, PhD, Angel F. Lopez, MBBS, PhD, Andrew Nash, PhD
Journal: Blood
Blood (2012) 120 (21): 3598.
https://doi.org/10.1182/blood.V120.21.3598.3598
Published: 2012
Journal Articles

A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML

Andrew W. Roberts, MBBS, PhD, Simon He, MBBS, Kenneth F Bradstock, MB, PhD, FRACP, FRCPA, Mark S Hertzberg, MBBS, FRACP, FRCP, PhD, Simon T S Durrant, MRCS, MBBS, MRCP, FRCP, David Ritchie, MBChB, FRACP, FRCPA, PhD, Ian D. Lewis, MBBS, PhD, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA, Andrew J McLachlan, PhD, Trina M Yeadon, PhD, Samantha J Busfield, PhD, Megan J Barnden, PhD, Roslyn Davis, BSc(Hons), Sarah Hosback, PhD, Danijela Mirosa, PhD, Mark Biondo, PhD, Simone Bamford, MBBS, FRACGP, Mark DeWitte, VMD, Russell Basser, MBBS, MD, FRACP
Journal: Blood
Blood (2008) 112 (11): 2956.
https://doi.org/10.1182/blood.V112.11.2956.2956
Published: 2008
Journal Articles

Preliminary Results of CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb), in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.

Robert F. Manges, MD, Heather J. Sutherland, MD, Sundar Jagannath, MD, Robert Z. Orlowski, MD, PhD, David La Police, Mark DeWitte, VMD, Zhihui Lang, MD, PhD, Robert E. Corringham, MD, Jean Francois Rossi, MD
Journal: Blood
Blood (2007) 110 (11): 1183.
https://doi.org/10.1182/blood.V110.11.1183.1183
Published: 2007